excede

Excede is a brand-name veterinary antibiotic containing ceftiofur crystalline free acid (CCFA), a long-acting cephalosporin. It is used in cattle and pigs to treat certain bacterial infections, most notably bovine respiratory disease and related conditions, with a single administration often providing extended exposure to the drug.

Indications and usage vary by country, but Excede is commonly indicated for treatment of bovine respiratory disease in calves and nonlactating cattle, as well as certain soft tissue and infectious conditions such as interdigital necrobacillosis in cattle. In swine, it has been used for management of respiratory disease under veterinary supervision. The product is designed to be given as a subcutaneous injection and typically dosed at 6.6 mg/kg, delivering sustained plasma levels for several days and reducing the need for multiple daily treatments.

Pharmacology and mechanism of action: ceftiofur is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to bacterial death. The crystalline free acid formulation provides a prolonged release, contributing to its long-acting profile.

Administration and pharmacokinetics: Excede is administered by a single subcutaneous injection. The long-acting formulation maintains drug concentrations above the effective level for a period of days, enough to simplify treatment regimens in herd settings.

Safety and regulation: use should follow veterinary guidance and label directions. Meat and milk withdrawal intervals are specified on the product label to prevent drug residues. Possible adverse effects include injection-site reactions or rare hypersensitivity in susceptible animals.

History: Excede was developed for veterinary use by Pfizer Animal Health and, after corporate changes, is marketed by Zoetis. It has been available in multiple countries since the early 2000s. See also ceftiofur, bovine respiratory disease, and cephalosporins.